Novo Nordisk Annual Sales Jump on Higher Demand for Obesity Drugs
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...
Wegovy sales double to boost Novo Nordisk's fourth quarter as growth set to slow
Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, ...
Novo Nordisk: Among The Best Opportunities Of The Moment (Rating Upgrade)
Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.
devdiscourse2d
Health News Highlights: Stable Pig Prices, Investor Concerns, and Medical Developments
This summary covers recent health news, including stable pig prices in Germany, investor focus on AstraZeneca's China probe, ...
Novo Nordisk Stock Rises as Q4 Wegovy Sales More Than Double
Novo Nordisk's U.S.-listed shares are rising 4% in premarket trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid ...
DZ BANK AG Sticks to Their Hold Rating for Novo Nordisk (0QIU)
In a report released today, Elmar Kraus from DZ BANK AG maintained a Hold rating on Novo Nordisk (0QIU – Research Report). The company’s shares ...
devdiscourse9d
Health Headlines: Diphtheria Tragedy, Vaccine Scrutiny, and Insulin Caps
This comprehensive health news roundup highlights a tragic diphtheria case in Germany, vaccine and abortion-related scrutiny ...